Oxford Biomedica plc (LSE: OXB)

https://www.oxfordbiomedica.co.uk

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. *

	Start	1996-01-01 splitoff predec
	Group	Oxford Biomedica (Group)
	Predecessor	Oxford Biomedica Ltd.
	Industry	gene therapy
	Person	Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe)
	Person 2	Paynter, Stuart (Oxford BioMedica 201708– CFO before De La Rue plc + Shire Pharmaceuticals + Steris)

	Region	Oxford, Oxfordshire
	Country	United Kingdom (GB)
	Street	Windrush Court Transport Way
	City	OX4 6LT Oxford
	Tel	+44-1865-783000
		Address record changed: 2020-12-02

Basic data	Employees	E: 501 to 1,000 (2020-03-18)
	Currency	GBP
	Annual sales	65,000,000 (revenue, total, consolidated (2019) 2019-12-31)
	Profit	7,541,000 (2018-12-31)
	Cash	16,000,000 (2019-12-31)

		* Document for ï¿½About Sectionï¿½: Oxford Biomedica plc. (3/18/20). "Press Release: Building the Group for Future Growth. Business Update". Oxford.

		Record changed: 2021-05-18